

## Special Issue

# Efforts to Mitigate the Toxicity of Cancer Therapeutics

### Message from the Guest Editor

With improvements in cancer therapeutics that have extended the lives of cancer patients, it becomes critical to also consider the impact of these treatments on patient quality of life. The toxicities of both cancer chemotherapeutic drugs and radiation therapy include peripheral neuropathy (vinca alkaloids, taxanes, platinum compounds and bortezomib), chemobrain (various drugs alone and in combination), arthralgia (aromatase inhibitors), delayed cardiotoxicity (doxorubicin), renal injury (platinum compounds), fibrosis (radiation) and severe delayed onset diarrhea (irinotecan), among others. With some exceptions, the basis for these toxicities is uncertain and there are few, if any, useful approaches for preventing or treating these “side effects”. The goals of this special issue are to explore the progress of current research efforts to mitigate the toxic and often severe and persistent impact of current standard of care therapies in cancer.

### Guest Editor

Prof. Dr. David A. Gewirtz

Department of Pharmacology and Toxicology and Medicine, Virginia Commonwealth University, Richmond, VA 23284, USA

### Deadline for manuscript submissions

closed (31 January 2021)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/43955](https://mdpi.com/si/43955)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)